Cristian Massacesi

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari et al. · The Lancet · 2017 · 1.1K citations

Medicine, Bronchial Neoplasm, Advanced Alk +8

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Alice T. Shaw, Tae Min Kim, Lucio Crinò et al. · The Lancet Oncology · 2017 · 574 citations · Full text

Medicine, Ceritinib Versus Chemotherapy, Pathology +6

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

José Baselga, Seock‐Ah Im, Hiroji Iwata et al. · The Lancet Oncology · 2017 · 532 citations · Full text

Advanced Breast Cancer, Breast Oncology, Oncology +13

Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

Daniele Santini, Bruno Vincenzi, Giordano Dicuonzo et al. · PubMed · 2003 · 356 citations

Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab

Fabrice André, Mario Campone, Ruth O’Regan et al. · Journal of Clinical Oncology · 2010 · 206 citations